#USA #Boston #Nanomosaic #Dr. Anne Marie Morse #Tessie

Appointment of Dr. Anne Marie Morse

In a significant move to bolster its clinical leadership, NanoMosaic, Inc. has announced the appointment of Dr. Anne Marie Morse as the Chairwoman of its newly established Clinical Advisory Board. Dr. Morse, known for her expertise in neurology and sleep medicine, will play a pivotal role in collaborating with pharmaceutical partners to seamlessly integrate ultra-sensitive companion diagnostics throughout the drug development lifecycle. This ranges from early discovery right through to regulatory approval and commercialization.

Enhancing Patient Identification and Trial Efficiency

Dr. Morse's primary focus will be to guide the deployment of innovative diagnostic tools from NanoMosaic, which are designed to act as scalable solutions for population health. With her leadership, the aim is to enable earlier patient identification, enhance trial efficiency, and ensure therapies are precisely delivered to individuals who stand to benefit the most.

At the heart of this initiative is the Tessie™ platform — a groundbreaking, portable diagnostic system engineered to provide laboratory-grade sensitivity directly at the point of need. Tessie facilitates direct measurements from a variety of crude biological samples, such as plasma, saliva, tears, and even cerebrospinal fluid, all without requiring purification.

Speed and Precision in Diagnostics

A standout feature of the Tessie platform is its ability to detect ultra-low-abundance biomarkers with femtogram-per-milliliter sensitivity. Remarkably, results can be obtained in just 7.5 seconds per sample, which is crucial for real-time clinical decision-making.

This rapid deployment strategy eliminates the need for clean-room facilities, allowing for immediate setup in decentralized clinical trial recruitment and screening processes. With Tessie, pharmaceutical companies can start identifying patient responders more swiftly, ultimately improving trial power while simultaneously lessening patient burden.

A Vision for Transformation

Expressing her enthusiasm, Dr. Morse stated, "I am incredibly excited to embrace my new role as Chair of the Clinical Advisory Board for NanoMosaic. I envision NanoMosaic as a truly transformative force—a U.S.-based, cost-effective, and efficient platform that will elevate the standard of care in neurology and beyond. Its potential for precise diagnostics and innovative biomarker assays positions it to make a profound impact on population health while supporting the individualized patient journey."

The integration of Tessie into pharmaceutical development is structured to align with both clinical and commercial imperatives. This dual approach allows companies to optimize the design of their trials while simultaneously validating companion diagnostics for widespread market adoption.

Accelerating Precision Medicine

John Boyce, Chairman and Co-Founder of NanoMosaic, commented on Dr. Morse's leadership, emphasizing that it strengthens their mission to bring precision medicine closer to patients. He noted, "By enabling real-time, ultra-sensitive diagnostics outside of traditional lab settings, we can streamline how therapies reach patients, accelerate care, and alleviate suffering by getting the right treatments to the right people faster."

About Dr. Anne Marie Morse

Dr. Anne Marie Morse has earned recognition as a leading neurologist and sleep medicine specialist. Her extensive career includes serving as Director of Child Neurology and Pediatric Sleep Medicine, as well as establishing and directing a child neurology residency program. She is also known for her contributions to digital transformation initiatives and her advisory roles in various pharmaceutical and biotechnology ventures. Dr. Morse is a highly regarded educator and a passionate advocate for patient care.

About NanoMosaic Inc.

NanoMosaic is an innovative diagnostics firm focused on developing ultra-sensitive, rapid, and portable platforms for biomarker measurement. The advanced Tessie™ system enhances real-time decision-making capabilities from raw biological samples, paving the way for advancements in companion diagnostics, clinical trial recruitment, and precision medicine across neurology and other fields.